<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03261375</url>
  </required_header>
  <id_info>
    <org_study_id>GL-CT-20170821</org_study_id>
    <nct_id>NCT03261375</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate Safety and Efficacy of a Renal Denervation System in Treatment of Hypertension</brief_title>
  <official_title>A Prospective, Multicentre, Randomized, Controlled Trial for Safety and Efficacy of a Renal Denervation System in Treatment of Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Golden Leaf MedTec Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Golden Leaf MedTec Co. Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentre clinical trial to evaluate safety and efficacy of renal denervation
      system in treatment of hypertension. Hypertensive patients who meet enrollment criteria will
      be randomized into treatment group who will receive standardized drugs and renal denervation
      treatments, or control group who will receive standardized drugs and a sham procedure (renal
      artery angiography only without denervation). The patients will be monitored for blood
      pressure changes and any adverse events for 6 months. The safety and efficacy of the device
      will be evaluated by comparing blood pressure levels and adverse event episodes between the
      two groups.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 27, 2017</start_date>
  <completion_date type="Anticipated">August 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>6 months</time_frame>
    <description>clinical blood pressure levels</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Primary Hypertension, Chronic Kidney Diseases (CKD) Hypertension</condition>
  <arm_group>
    <arm_group_label>Renal denervation (RDN) Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Renal Denervation System</intervention_name>
    <description>A renal denervation system with a 6 electrodes-on-net structure catheter</description>
    <arm_group_label>Renal denervation (RDN) Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antihypertensive Agents</intervention_name>
    <description>Calcium channel blocker，Diuretic</description>
    <arm_group_label>Renal denervation (RDN) Group</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Procedure</intervention_name>
    <description>Catheterization without renal denervation</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages of 18 to 65, male or female;

          -  Patients who have been taking 2 or more anti-hypertensive drugs for at least 4 weeks,
             with mean BP ≥150/90 mmHg based on 3 office blood pressure measurements, or ASBP≥135
             mmHg based on 24 hr blood pressure monitoring;

          -  Heart beats at rest ≥70 bpm

          -  Confirmed diagnosis of primary hypertension or CKD hypertension;

          -  Main renal artery, with or without accessary renal arteries;

          -  Agrees to take part in the trial and signs the written, informed consent.

        Exclusion Criteria:

          -  Pregnant or plan to become pregnant, or Breastfeeding;

          -  Renal artery abnormalities that are inappropriate for the procedure (renal stenosis
             ≥50%, aneurysm, renal artery diameter &lt;4mm or length&lt;20mm) ;

          -  Only one kidney or kidney transplant recipient

          -  Prior renal artery interventional procedures or prior RDN treatment;

          -  Any conditions affecting accuracy of blood pressure measurement, such as diameter of
             upper arm too large for the cuff or severe arrhythmia;

          -  Secondary hypertension other than CKD hypertension;

          -  Pseudohypertension;

          -  History of orthostatic hypotension;

          -  Average systolic blood pressure (ASBP) &lt;135mmHg based on ambulatory 24 hours blood
             pressure monitoring;

          -  History of hospitalization for hypertensive emergencies within one year;

          -  Type I diabetes;

          -  Primary pulmonary hypertension;

          -  Bleeding tendency or other coagulation related diseases;

          -  Abnormal blood electrolytes levels;

          -  History of stroke or transit ischemic attack (TIA) within 2 weeks;

          -  Malignant tumor or end-stage illnesses;

          -  Severe peripheral vascular diseases, aneurysm;

          -  Acute coronary events within 2 weeks;

          -  Patients who need assisted breathing with mechanical ventilation;

          -  Acute or severe systemic infection;

          -  Patients with pacemaker implantation;

          -  Major surgery or trauma in 30 days before enrollment;

          -  Plan to receive surgery or cardiovascular interventional procedures in 6 months;

          -  Have been enrolled for other drug or device trial;

          -  Known drug or alcohol dependency, unable to comprehend the trial protocol, unwilling
             or unable to comply with follow-ups in accordance with the protocol;

          -  Other conditions that deem unsuitable for the procedure, in the opinions of
             investigators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yujie Zhou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Anzhen Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hua Q Yin, PhD</last_name>
    <phone>86-21-54868750</phone>
    <phone_ext>201</phone_ext>
    <email>huaqing.yin@goldenleafmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yujie Zhou, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Chaoyang Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xinchun Yang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Armed Police General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huiliang Liu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The 3rd Affiliated Hospital Jilin University</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping Yang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huaxi Hospital</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tianlei Cui, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The 1st Affiliated Hospital Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinzi Su, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Provincial People's Hospital</name>
      <address>
        <city>Hanzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiang He, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanjing Gulou Hospital</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Biao Xu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongda Hospital</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gengshan Ma, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuqiang Zhang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The 1st Affiliated Hospital Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pei Wang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The 1st Affiliated Hospital Xinjian Medical University</name>
      <address>
        <city>Ürümqi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiang Ma, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2017</study_first_submitted>
  <study_first_submitted_qc>August 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2017</study_first_posted>
  <last_update_submitted>August 24, 2017</last_update_submitted>
  <last_update_submitted_qc>August 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

